Neuburgh Advisers’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | $274K | Hold |
4,408
| – | – | 0.01% | 609 |
|
|
2019
Q2 | $314K | Buy |
4,408
+423
| +11% | +$30.1K | 0.01% | 579 |
|
|
2019
Q1 | $313K | Hold |
3,985
| – | – | 0.01% | 569 |
|
|
2018
Q4 | $337K | Hold |
3,985
| – | – | 0.01% | 500 |
|
|
2018
Q3 | $682K | Buy |
3,985
+106
| +3% | +$18.1K | 0.02% | 381 |
|
|
2018
Q2 | $501K | Hold |
3,879
| – | – | 0.02% | 426 |
|
|
2018
Q1 | $400K | Hold |
3,879
| – | – | 0.01% | 468 |
|
|
2017
Q4 | $331K | Buy |
3,879
+846
| +28% | +$72.2K | 0.01% | 526 |
|
|
2017
Q3 | $258K | Buy |
3,033
+600
| +25% | +$51K | 0.01% | 540 |
|
|
2017
Q2 | $184K | Buy |
2,433
+1,128
| +86% | +$85.3K | 0.01% | 594 |
|
|
2017
Q1 | $86K | Buy |
1,305
+247
| +23% | +$16.3K | ﹤0.01% | 653 |
|
|
2016
Q4 | $67K | Buy |
+1,058
| New | +$67K | ﹤0.01% | 680 |
|